VEL-101

VEL-101, formerly FR104, is an experimental monovalent, pegylated fab' antibody against CD28. It is developed for transplant rejection and autoimmune diseases.{{cite journal |last1=Ville |first1=Simon |last2=Poirier |first2=Nicolas |last3=Branchereau |first3=Julien |last4=Charpy |first4=Vianney |last5=Pengam |first5=Sabrina |last6=Nerriere-Daguin |first6=Véronique |last7=Le Bas-Bernardet |first7=Stéphanie |last8=Coulon |first8=Flora |last9=Mary |first9=Caroline |last10=Chenouard |first10=Alexis |last11=Hervouet |first11=Jeremy |last12=Minault |first12=David |last13=Nedellec |first13=Steven |last14=Renaudin |first14=Karine |last15=Vanhove |first15=Bernard |last16=Blancho |first16=Gilles |title=Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection |journal=Journal of the American Society of Nephrology |date=December 2016 |volume=27 |issue=12 |pages=3577–3588 |doi=10.1681/ASN.2015070774|doi-access=free |pmc=5118475 }}{{cite journal |last1=Zhang |first1=T. |last2=Gheorghe |first2=B. |last3=Sun |first3=W. |last4=Rybak |first4=E. |last5=Harris |first5=D. |last6=Sievert |first6=E. |last7=Burdorf |first7=L. |last8=Cheng |first8=X. |last9=Vanhove |first9=B. |last10=Azimzadeh |first10=A. |last11=Pierson |first11=R. Iii |title=Effect of FR104, a Novel Anti-CD28 Fab, in Monkey Cardiac Allograft Transplantation.: Abstract# 1490 |journal=Transplantation |date=15 July 2014 |volume=98 |pages=33 |url=https://journals.lww.com/transplantjournal/Fulltext/2014/07151/Effect_of_FR104,_a_Novel_Anti_CD28_Fab,_in_Monkey.106.aspx |issn=0041-1337}}{{cite journal |last1=Poirier |first1=N. |last2=Mary |first2=C. |last3=Dilek |first3=N. |last4=Hervouet |first4=J. |last5=Minault |first5=D. |last6=Blancho |first6=G. |last7=Vanhove |first7=B. |title=Preclinical Efficacy and Immunological Safety of FR104, an Antagonist Anti-CD28 Monovalent Fab′ Antibody |journal=American Journal of Transplantation |date=October 2012 |volume=12 |issue=10 |pages=2630–2640 |doi=10.1111/j.1600-6143.2012.04164.x|doi-access=free }}{{cite journal |last1=Poirier |first1=N. |last2=Dilek |first2=N. |last3=Mary |first3=C. |last4=Ville |first4=S. |last5=Coulon |first5=F. |last6=Branchereau |first6=J. |last7=Tillou |first7=X. |last8=Charpy |first8=V. |last9=Pengam |first9=S. |last10=Nerriere-Daguin |first10=V. |last11=Hervouet |first11=J. |last12=Minault |first12=D. |last13=Le Bas-Bernardet |first13=S. |last14=Renaudin |first14=K. |last15=Vanhove |first15=B. |last16=Blancho |first16=G. |title=FR104, an Antagonist Anti-CD28 Monovalent Fab’ Antibody, Prevents Alloimmunization and Allows Calcineurin Inhibitor Minimization in Nonhuman Primate Renal Allograft |journal=American Journal of Transplantation |date=February 2015 |volume=15 |issue=1 |pages=88–100 |doi=10.1111/ajt.12964|doi-access=free }}{{cite journal |last1=Poirier |first1=Nicolas |last2=Blancho |first2=Gilles |last3=Hiance |first3=Maryvonne |last4=Mary |first4=Caroline |last5=Van Assche |first5=Tim |last6=Lempoels |first6=Jos |last7=Ramael |first7=Steven |last8=Wang |first8=Weirong |last9=Thepenier |first9=Virginie |last10=Braudeau |first10=Cecile |last11=Salabert |first11=Nina |last12=Josien |first12=Regis |last13=Anderson |first13=Ian |last14=Gourley |first14=Ian |last15=Soulillou |first15=Jean-Paul |last16=Coquoz |first16=Didier |last17=Vanhove |first17=Bernard |title=First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28 |journal=The Journal of Immunology |date=15 December 2016 |volume=197 |issue=12 |pages=4593–4602 |doi=10.4049/jimmunol.1601538|doi-access=free }}